Company Monitoring Page for Novartis

latest headlines for company on cafepharma

Being there: Amgen and Novartis roll out first ad campaign for migraine drug Aimovig
Fierce Pharma
Tue, 10/23/18 - 01:28 pm
Tags:
Novartis, Amgen, Aimovig, DTC ads, television ads
Battle Over Humira Begins in Europe as 5-Year Wait Begins in US
RAPS.org
Mon, 10/22/18 - 05:17 pm
Tags:
Europe, AbbVie, Humira, Amgen, Samsung Bioepis, Mylan Labs, Novartis, Sandoz, Fresenius Kabi, Boehringer Ingelheim
Novartis in constant evolution: new large investment in startup
GoinPharma
Sun, 10/21/18 - 11:31 pm
Tags:
Gamida Cell, IPOs, Novartis, NiCord
Novartis wants to blaze a trail in breast cancer with PIK3 drug
Pharmaforum
Sun, 10/21/18 - 11:26 pm
Tags:
Novartis, clinical trials, alpelisib, breast cancer
ESMO18: Novartis PI3K combo therapy boosts survival in subset of breast cancer patients
Fierce Biotech
Sat, 10/20/18 - 11:10 pm
Tags:
Europe, Novartis, ESMO, AstraZeneca, breast cancer, BYL719
NICE spurns Lilly’s breast cancer drug Verzenio in favor of rivals from Pfizer and Novartisspir
Fierce Pharma
Sat, 10/20/18 - 10:37 pm
Tags:
Lilly, Verzenio, breast cancer, Pfizer, Ibrance, Novartis, Kisqali, NICE
Novartis buys Endocyte for $2.1B in latest deal under CEO Narasimhan
Biopharma Dive
Thu, 10/18/18 - 01:08 pm
Tags:
Novartis, earnings, M&A, Endocyte
Are all new sales created equal?
EP Vantage
Wed, 10/17/18 - 10:28 am
Tags:
GSK, Pfizer, Novartis
Amgen, Novartis and Banner Alzheimer's Institute Team on 2 Alzheimer's Prevention Trials
BioSpace
Tue, 10/16/18 - 08:32 pm
Tags:
Amgen, Novartis, Alzheimer's disease, preventative medicine
7 drugmakers to watch during Q3 earnings
Biopharma Dive
Mon, 10/15/18 - 12:31 pm
Tags:
earnings, Novartis, Gilead Sciences, Amgen, Pfizer, GSK, AbbVie, Regeneron
Here's Why Momenta Pharmaceuticals Tumbled 13.5% on Friday
Motley Fool
Fri, 10/12/18 - 11:40 pm
Tags:
Momenta Pharmaceuticals, Teva Pharmaceuticals, Copaxone, Novartis, biosimilars, Glatopa
Sandoz free to launch Humira biosimilar in Europe following AbbVie deal
Pharmaforum
Fri, 10/12/18 - 10:24 am
Tags:
Novartis, Sandoz, AbbVie, Humira, biosimilars, Europe
Gilenya beats Copaxone head-to-head at higher dose, study finds
Biopharma Dive
Thu, 10/11/18 - 11:13 pm
Tags:
Novartis, Teva Pharmaceutical, MS, Copaxone, Gilenya
Roche and Novartis Strengthen Their Presence in the MS Market
BioSpace
Thu, 10/11/18 - 09:35 am
Tags:
Genentech, Roche, Ocrevus, Novartis, siponimod, FDA, MS, multiple sclerosis
Novartis drug cuts serious complications in sickle cell disease
CP WIre
Wed, 10/10/18 - 10:15 am
Tags:
Novartis, sickle cell disease, crizanlizumab
Novartis cozies up to Silicon Valley with new lab
Fierce Biotech
Tue, 10/9/18 - 11:32 am
Tags:
Novartis, innovation, San Francisco, Silicon Valley, R&D, Novartis Biome
Novartis bets PRV on its next big multiple sclerosis drug — eyes US, EU approvals in ’19
Endpoints
Mon, 10/8/18 - 10:45 am
Tags:
Novartis, siponimod, MS, multiple sclerosis, Europe
Moody's picks 5 early winners in biosimilar market
Biopharma Dive
Fri, 10/5/18 - 09:01 pm
Tags:
biosimilars, Pfizer, Biogen, Novartis, Amgen, Mylan Labs
Insight: How Novartis built a ‘money-filled moat’ to market Kymriah
Biopharma Reporter
Thu, 10/4/18 - 06:59 pm
Tags:
Novartis, Kymriah, competition, drug marketing, CAR-T
Boston Pharma Doubles Pipeline with 2 Deals with Novartis and GSK
BioSpace
Wed, 10/3/18 - 11:58 am
Tags:
Boston Pharmaceuticals, GSK, Novartis

Pages

last 30 twitter posts

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.